 |
|
Urine Detection of Survivin and Diagnosis of Bladder Cancer
Shannon D. Smith, MD;
Marcia A. Wheeler, MS;
Janet Plescia, BS;
John W. Colberg, MD;
Robert M. Weiss, MD;
Dario C. Altieri, MD
JAMA. 2001;285:324-328.
Context Dysregulation of apoptosis may favor onset and progression of cancer and influence response to therapy. Survivin is an inhibitor of apoptosis that is selectively overexpressed in common human cancers, but not in normal tissues, and that correlates with aggressive disease and unfavorable outcomes.
Objective To investigate the potential suitability of survivin detection in urine as a novel predictive/prognostic molecular marker of bladder cancer.
Design, Setting, and Patients Survey of urine specimens from 5 groups: healthy volunteers (n = 17) and patients with nonneoplastic urinary tract disease (n = 30), genitourinary cancer (n = 30), new-onset or recurrent bladder cancer (n = 46), or treated bladder cancer (n = 35), recruited from 2 New England urology clinics.
Main Outcome Measures Detectable survivin levels, analyzed by a novel detection system and confirmed by Western blot and reverse transcriptase polymerase chain reaction (RT-PCR), in urine samples of the 5 participant groups.
Results Survivin was detected in the urine samples of all 46 patients with new or recurrent bladder cancer using a novel detection system (31 of 31) and RT-PCR (15 of 15) methods. Survivin was not detected in the urine samples of 32 of 35 patients treated for bladder cancer and having negative cystoscopy results. None of the healthy volunteers or patients with prostate, kidney, vaginal, or cervical cancer had detectable survivin in urine samples. Of the 30 patients with nonneoplastic urinary tract disease, survivin was detected in 3 patients who had bladder abnormalities noted using cystoscopy and in 1 patient with an increased prostate-specific antigen level. Patients with low-grade bladder cancer had significantly lower urine survivin levels than patients with carcinoma in situ (P = .002).
Conclusions Highly sensitive and specific determination of urine survivin appears to provide a simple, noninvasive diagnostic test to identify patients with new or recurrent bladder cancer.
Author Affiliations: Departments of Surgery (Drs Smith, Colberg, and Weiss, and Ms Wheeler) and Pathology (Ms Plescia and Dr Altieri), Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Conn.
RELATED ARTICLE
January 17, 2001
JAMA. 2001;285(3):347-348.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Mita et al.
Clin. Cancer Res. 2008;14:5000-5005.
ABSTRACT
| FULL TEXT
The Universal Character of the Tumor-Associated Antigen Survivin
Andersen et al.
Clin. Cancer Res. 2007;13:5991-5994.
ABSTRACT
| FULL TEXT
Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer
Black et al.
JCO 2006;24:5528-5535.
ABSTRACT
| FULL TEXT
Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality
Muller and Brenner
Clin. Chem. 2006;52:562-573.
ABSTRACT
| FULL TEXT
Targeted therapy by disabling crossroad signaling networks: the survivin paradigm.
Altieri
Molecular Cancer Therapeutics 2006;5:478-482.
ABSTRACT
| FULL TEXT
Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer
Sanchini et al.
JAMA 2005;294:2052-2056.
ABSTRACT
| FULL TEXT
A Survivin Gene Signature Predicts Aggressive Tumor Behavior
Salz et al.
Cancer Res. 2005;65:3531-3534.
ABSTRACT
| FULL TEXT
Survivin: A Bifunctional Inhibitor of Apoptosis Protein
Johnson and Howerth
Vet Pathol 2004;41:599-607.
ABSTRACT
| FULL TEXT
Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice
Schimmer
Cancer Res. 2004;64:7183-7190.
ABSTRACT
| FULL TEXT
Enzyme Immunoassay for Serum Autoantibody to Survivin and Its Findings in Head-and-Neck Cancer Patients
Chang et al.
Clin. Chem. 2004;50:1261-1264.
FULL TEXT
Identification by Proteomic Analysis of Calreticulin as a Marker for Bladder Cancer and Evaluation of the Diagnostic Accuracy of Its Detection in Urine
Kageyama et al.
Clin. Chem. 2004;50:857-866.
ABSTRACT
| FULL TEXT
Full-Length Dominant-Negative Survivin for Cancer Immunotherapy
Pisarev et al.
Clin. Cancer Res. 2003;9:6523-6533.
ABSTRACT
| FULL TEXT
Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer
Gazzaniga et al.
Ann Oncol 2003;14:85-90.
ABSTRACT
| FULL TEXT
Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer
Sanchez-Carbayo
Clin. Chem. 2003;49:23-31.
ABSTRACT
| FULL TEXT
Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas
Chakravarti et al.
JCO 2002;20:1063-1068.
ABSTRACT
| FULL TEXT
Can Urinary Survivin Level Predict Bladder Cancer?
JWatch General 2001;2001:2-2.
FULL TEXT
|
